DDInter1294 DDInter1409
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Nilutamide {u} (Compound) resembles {v} (Compound) Nitisinone
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Nilutamide {u} (Compound) treats {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Nilutamide {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Eltrombopag
Eltrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Lurbinectedin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Nilutamide {u} (Compound) resembles {v} (Compound) Nitisinone
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Tucatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Nilutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Androgen Receptor Antagonists {u} (Pharmacologic Class) includes {v} (Compound) Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Nilutamide {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Meloxicam
Meloxicam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide (Compound) resembles Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Nilutamide (Compound) resembles Nitisinone (Compound) and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Nilutamide (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is treated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Nilutamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Eltrombopag (Compound) and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Nilutamide (Compound) resembles Nitisinone (Compound) and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Nilutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class) and Androgen Receptor Antagonists (Pharmacologic Class) includes Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Nilutamide (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Meloxicam (Compound) and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a